新诺威(300765) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥524,066,868.93, a decrease of 27.08% compared to ¥718,720,405.00 in the same period last year[5] - Net profit attributable to shareholders was ¥79,061,260.62, down 38.86% from ¥129,302,283.05 year-on-year[5] - Basic and diluted earnings per share were both ¥0.0676, representing a decrease of 40.44% from ¥0.1135 in the previous year[5] - Total operating revenue for Q1 2024 was CNY 524.07 million, a decrease of 27.1% compared to CNY 718.72 million in the same period last year[23] - Net profit for Q1 2024 was CNY 29.96 million, a decline of 61.9% compared to CNY 78.65 million in Q1 2023[24] Cash Flow - The net cash flow from operating activities was -¥975,365,408.34, a decline of 429.29% compared to ¥296,205,970.86 in Q1 2023[12] - Total cash inflow from operating activities was ¥576,280,891.81, while cash outflow was ¥1,551,646,300.15, resulting in a significant cash outflow[27] - The net cash flow from investing activities was -¥73,801,694.62, compared to -¥108,186,330.64 in the previous year[27] - Cash inflow from financing activities was ¥488,799,998.48, while cash outflow was ¥35,839,858.64, leading to a net cash flow of -¥35,839,858.64[28] - The company’s cash and cash equivalents decreased by ¥1,083,888,306.89 during the quarter[28] Assets and Liabilities - Total assets at the end of the reporting period were ¥6,467,210,851.42, down 13.45% from ¥7,472,208,452.03 at the end of the previous year[5] - The total liabilities decreased to CNY 989.34 million in Q1 2024 from CNY 1,988.94 million in the previous year[23] - The total equity attributable to shareholders of the parent company increased to CNY 4,407.73 million from CNY 4,364.03 million year-over-year[23] Investment and Shareholder Information - The company reported an investment loss of -¥4,612,266.72, an increase of 554.56% compared to -¥704,630.92 in the same period last year[10] - The largest shareholder, Shiyao Group Enbi Pharmaceutical Co., Ltd., holds 73.58% of shares, totaling 861,453,662 shares[14] - The total number of common shareholders at the end of the reporting period is 19,048[14] - The number of restricted shares held by Shiyao Group Enbi Pharmaceutical Co., Ltd. is 131,267,092, with a release date set for November 14, 2025[16] Operational Metrics - The company attributed the decline in revenue primarily to a decrease in the price of caffeine products and the ongoing R&D phase of its pipeline products[10] - Research and development expenses for Q1 2024 were CNY 110.48 million, a reduction of 21.4% compared to CNY 140.59 million in the same period last year[23] - Accounts receivable increased to ¥467,058,782.66 from ¥392,376,024.64, reflecting a growth of approximately 19.0%[20] - Inventory has risen to ¥262,035,961.41, up from ¥224,821,141.86, indicating an increase of about 16.6%[20] Other Financial Activities - The company received tax refunds amounting to ¥8,848,717.39 during the quarter[27] - Cash received from other operating activities totaled ¥81,292,579.67[27] - The company paid ¥66,791,807.46 to employees during the quarter[27] - The company reported a cash inflow of ¥1,396,261.00 from the disposal of fixed assets and other long-term assets[27]